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Abstract: Since the early 1960s, a compelling body of evidence has accumulated to show that 
proteinases play critical roles in airspace enlargement in chronic obstructive pulmonary disease 
(COPD). However, until recently the causative enzymes and their exact roles in pathologic 
processes in COPD have not been clear. Recent studies of gene-targeted mice in murine models 
of COPD have conﬁ  rmed roles for proteinases not only in airspace enlargement, but also in 
airway pathologies in COPD. These studies have also shed light on the speciﬁ  c proteinases 
involved in COPD pathogenesis, and the mechanisms by which these proteinases injure the 
lung. They have also identiﬁ  ed important interactions between different classes of proteinases, 
and between proteinases and other molecules that amplify lung inﬂ  ammation and injury. This 
review will discuss the biology of proteinases and the mechanisms by which they contribute to 
the pathogenesis of COPD. In addition, I will discuss the potential of proteinase inhibitors and 
anti-inﬂ  ammatory drugs as new treatment strategies for COPD patients.
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Introduction
COPD is currently the fourth most common cause of death in the USA, and its inci-
dence is increasing, especially in women, worldwide and in third-world countries. The 
National Heart, Lung, and Blood Institute has estimated the annual costs of COPD in 
the USA in 2005 to be US$38.8 billion. COPD is the least well-funded disease relative 
to its global heath burden. As a result of the huge healthcare burden associated with 
COPD, there has been a resurgence of interest in its cellular and molecular mechanisms, 
and in the development of new treatment strategies to limit the deleterious effects of 
proteinases in the lungs of COPD patients.
Pathology
In developed countries, the main risk factor for COPD is smoking cigarettes, which 
accounts for more than 95% of all cases. Other risk factors include inhalation of pol-
lutants, wood smoke, and biomass fuels in enclosed spaces in third-world countries. 
Genetic factors may also increase individual susceptibility to the adverse effects of 
cigarette smoke, or alter normal lung repair processes. Inhalation of cigarette smoke 
and other pollutants leads to a chronic inﬂ  ammatory process in the small airways and 
the lung parenchyma including macrophages, polymorphonuclear neutrophils (PMN), 
T lymphocytes (with CD8+ T cells exceeding the numbers of CD4+ T cells), and 
B lymphocytes (Di Stefano et al 1996; Saetta 1999; Turato et al 2001; Hogg et al 2004). 
Over time, there is destruction of the alveolar walls leading to airspace enlargement, 
loss of lung elasticity, closure of small airways, and irreversible airﬂ  ow obstruction. 
Pathological changes also develop in the airways, including mucus metaplasia and 
mucus hyper-secretion. Narrowing of the small airways develops as a result of mucus International Journal of COPD 2008:3(2) 254
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plugging, inﬂ  ammation in the airway walls and lumen, and 
subepithelial ﬁ  brosis. This small airway obstruction is also 
an important determinant of the ﬁ  xed airﬂ  ow obstruction 
that occurs in COPD patients (Hogg et al 2004). Although 
COPD is a complex disorder caused by multiple mediators 
and pathways (including reactive oxygen species [ROS], 
pro-inﬂ  ammatory mediators, apoptosis of structural cells, 
and inadequate repair processes), there is strong evidence that 
proteinases make critical contributions to all the pathologic 
processes detected in the lungs of COPD patients.
Historical aspects of proteinases 
in COPD:   The proteinase-
antiproteinase hypothesis
Two observations in the 1960s, one clinical and one experi-
mental, led to the proteinase/antiproteinase hypothesis for 
the pathogenesis of emphysema. The ﬁ  rst observation was 
that genetic deﬁ  ciency of α1-proteinase inhibitor ([α1-PI], 
which is the major inhibitor of neutrophil elastase [NE] in the 
lower respiratory tract) is associated with early-onset, severe 
panlobular pulmonary emphysema (Laurell and Eriksson 
1963). The second observation was that instillation of papain 
(a metalloproteinase with elastin-degrading activity) into 
rat lungs results in progressive airspace enlargement (Gross 
et al 1965). Since then, other proteinases that degrade lung 
elastin, including porcine pancreatic elastase (Karlinsky et al 
1983) and subsequently NE and proteinase 3 (PR3), which 
are more relevant to human COPD compared to porcine 
pancreatic elastase, were shown to enlarge airspaces when 
instilled into the lungs of experimental animals (Senior 
et al 1977; Kao et al 1988). Based upon these observations 
the proteinase-anti-proteinase hypothesis was formulated: 
Inhalation of cigarette smoke (or other pollutants) leads 
to the recruitment of inﬂ  ammatory cells into the lungs. 
Inﬂ  ammatory cells release various proteinases that exceed 
the proteinase inhibitor defense of the lung. Uncontrolled 
proteinases degrade the extracellular matrix (ECM) protein 
components of the alveolar walls (especially the elastic 
ﬁ  bers) leading to destruction and loss of the alveolar walls 
and airspace enlargement (Figure 1).
Because of the association between α1-PI deﬁ  ciency 
and pulmonary emphysema, early studies focused on the 
role of NE in airspace enlargement. While unrestrained NE 
activity in the lung is likely to be important in the panlobular 
pulmonary emphysema associated with α1-PI deﬁ  ciency, this 
is probably an oversimpliﬁ  cation of mechanisms underlying 
the majority of COPD patients, who have normal plasma 
levels of α1-PI. Studies during the last 3–4 decades have 
identiﬁ  ed roles for other proteinases in airspace enlargement, 
roles for proteinases in airways pathologies (Figure 1), and 
important interactions between different classes of protein-
ases and between proteinases and other molecules (eg, ROS 
and inﬂ  ammatory mediators) that amplify inﬂ  ammation and 
ECM destruction in COPD.
Classiﬁ  cation and biology 
of proteinases
Proteinases cleave the internal peptide bonds of polypeptides. 
They can be classiﬁ  ed into 4 groups by the chemical nature 
of their active site: serine, metallo-, cysteine, and aspartic 
proteinases (Table 1). Proteinase inhibitors are generally 
targeted against individual classes of proteinases (Table 1). 
Serine proteinases and MMPs are optimally active at neutral 
pH and have the largest role in extracellular proteolysis. 
Cysteine and aspartic proteinases are optimally active at 
acidic pH, and their main role is in intracellular degradation 
of proteins in lysosomes. However, acid proteinases can 
degrade extracellular proteins if they retain catalytic activity 
at neutral pH or are released into an environment having an 
acidic pH, such as the pericellular environment of activated 
macrophages (Mason et al 1986; Shi et al 1992). The pro-
teinases implicated in the pathogenesis of COPD belong to 
the serine, metallo-, and cysteine proteinase classes.
Serine proteinases
Serine proteinases implicated in COPD include PMN-derived 
serine proteinases, urokinase-type plasminogen activator 
(uPA), granzymes, and plasmin (Table 1).
PMN-derived serine proteinases
These include NE, PR3, and cathepsin G (CG). PMN and 
pro-inﬂ  ammatory monocytes store preformed serine pro-
teinases in their primary granules, from which the enzymes 
are released when pro-inﬂ  ammatory mediators induce PMN 
degranulation (Owen et al 1994; Owen and Campbell 1999). 
Together, these serine proteinases have a broad spectrum of 
activity against ECM proteins (especially elastin) and non-
ECM proteins (Owen and Campbell 1999).
Urokinase-type plasminogen activator (uPA)
This enzyme is expressed by PMN, monocytes, and macro-
phages. Preformed uPA is stored in and released from the 
speciﬁ  c granules of PMN. However, uPA expression is regu-
lated at the transcriptional level in mononuclear phagocytes 
by pro-inﬂ  ammatory mediators (Granelli-Peperno et al 1977; 
Vassalli et al 1991). Following its release from cells, uPA binds International Journal of COPD 2008:3(2) 255
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to a speciﬁ  c receptor (uPA receptor) on phagocyte surfaces, 
where it functions as a cell-associated proteinase. The main 
function of uPA is to convert inactive plasminogen to active 
plasmin, another serine proteinase. Plasmin degrades ﬁ  brin 
during lysis of blood clots. However, plasmin also cleaves and 
activates latent growth factors, latent proMMPs, and protease-
activated receptor-1 (PAR-1) on macrophages, which drives 
macrophage MMP-12 production (Saksela and Rifkin 1988; 
Taipale et al 1992; Raza et al 2000; Churg et al 2007b). Thus 
by generating plasmin, uPA regulates not only ﬁ  brinolysis, but 
also ECM degradation and ﬁ  brotic processes in the lung.
Granzymes (GRZ)
Granzymes are granule-associated enzymes that are 
predominantly expressed by CD8+ T lymphocytes and are 
stored in the lytic granules of these cells (Smyth et al 1996). 
The main GRZ family members in human CD8+ T cells are 
GRZ A and B. Activation of CD8+ T cells by antigen leads 
to rapid exocytosis of GRZ and perforin-containing granules. 
Perforin alters the properties of the cell membrane of the 
target cells, allowing entry of GRZ into the target cell, and 
GRZ A and GRZ B then initiate caspase-independent and 
caspase-dependent apoptosis, respectively.
Serine proteinase inhibitors
Serine proteinase inhibitors in plasma and interstitial ﬂ  uids 
include α1-PI, α1-antichymotrypsin, plasminogen activator 
inhibitors, α2-plasmin inhibitor, and the universal inhibitor, 
α2-macroglobulin (α2-M), which inhibits all four classes 
of enzymes (Carrell 1986). Secretory leukocyte proteinase 
inhibitor (SLPI) and elaﬁ  n are synthesized locally in the 
respiratory tract by epithelial cells.
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Figure 1 Mechanisms by which different classes of proteinases contribute to pathologies in COPD. Cigarette smoke stimulates inﬂ  ammatory cell recruitment, proteinase 
production, and proteinase release from inﬂ  ammatory, immune, and structural cells in the lung. Proteinases contribute to airspace enlargement by degrading ECM and promoting 
death of structural cells of the alveolar walls. Proteinases also amplify lung inﬂ  ammation and promote mucus hypersecretion and small airway ﬁ  brosis.
Abbreviations: COPD, chronic obstructive pulmonary disease; ECM, extracellular matrix; MAC, macrophages; PMN, polymorphonuclear neutrophils; IP-10, interferon-γ 
-inducible protein-10; SP, serine proteinases; MMP, matrix metalloproteinases; ADAMs, proteinases with a disintegrin and a metalloproteinase domain; CP, cysteine proteinases; 
GRZ, granzymes.International Journal of COPD 2008:3(2) 256
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Metalloproteinases
This class of proteinases includes the matrix metalloprotein-
ases (MMPs) and members of the ADAMs family.
MMPs
MMPs have an NH2 terminal pro domain, an active site 
zinc atom, and a COOH terminal hemopexin domain that 
regulates the binding of the enzymes to their substrates. 
MMPs are generally produced as inactive proenzymes 
(proMMPs). Latency is maintained by an interaction 
between the active site zinc atom and a conserved cysteine 
residue in the pro domain. Activation of proMMPs occurs 
when this interaction is disrupted, which may be achieved 
by the actions of other proteinases and oxidants in the 
extracellular space (the cysteine switch mechanism of 
activation of proMMPs [Murphy et al 1999; Fu et al 2001]). 
Some MMPs are activated in the transgolgi by cleavage of 
the prodomain by furin, an intracellular serine proteinase 
(Imai et al 1996; Cao et al 2005). MMPs are generally 
synthesized de novo by cells activated by pro-inﬂ  ammatory 
mediators or growth factors. However, PMN store 
preformed MMP-8, MMP-9, and MT6-MMP (MMP-25) 
in their cytoplasmic granules, from which the enzymes 
are released when PMN degranulate (Owen and Campbell 
1999). Macrophages express MMPs-1, -3, -7, -9, -12, 
and -14 (Shapiro et al 1991; Rajavashisth et al 1999), and 
lung epithelial cells and ﬁ  broblasts produce MMPs-2, -9, and -
14. MMPs are subdivided into 6 groups based upon a similar 
domain organization and substrate speciﬁ  city including: 1) 
the interstitial collagenases (MMPs-1, -8, and -13); 2) the 
gelatinases (MMPs-2 and -9); 3) the stromelysins (MMPs-3, 
-10, and -11); 4) matrilysin (MMP-7); 5) metalloelastase 
(MMP-12); and 6) membrane-type MMPs (MT-MMPs), 
which are integral membrane proteinases having either a 
transmembrane domain or a glycosylphosphatidyl-inositol 
anchor to the cell membrane (Sato et al 1994; Takino 
et al 1995). The interstitial collagenases degrade interstitial 
collagens. The other subgroups have broader substrate 
specificities including denatured collagens (gelatins), 
basement membrane proteins, and pro-inflammatory 
mediators. MMPs-7, -9, and -12 also degrade elastin (Owen 
and Campbell 1999).
ADAM
ADAMs are a family of type I transmembrane protein-
ases, so called because they contain a disintegrin and a 
metalloproteinase domain (Primakoff and Myles 2000). 
The metalloproteinase domain of ADAMs sheds mem-
brane-anchored cytokines such as pro-tumor necrosis 
factor (TNF-α), other cytokines, growth factors, apoptosis 
Table 1 Proteinases involved in the pathogenesis of COPD
Class of
proteinase
Optimum
pH
Examples Sources Inhibitors
Serine
proteinases
Neutrophil elastase (NE)
Cathepsin G (CG)
Proteinase 3 (PR3)
PMN
P Monocytes
α1-proteinase inhibitor (α1-PI)
α1-antichymotrypsin (α1-Ach)
Secretory leukocyte protease 
inhibitor (SLPI) Elaﬁ  n
α2-macroglobulin (α2M)
Neutral Urokinase-type plasminogen 
Activator (uPA)
Granzymes
Thrombin
Plasmin
PMN, monocytes, macrophages
CD8+ T cells, NK cells
Plasma
Plasminogen in plasma
Plasminogen activator inhibi-
tors (PAI)
Not known
Anti-thrombin III, α1-PI
α2-antiplasmin, α1-PI
Metallo-
proteinases
Neutral Matrix metalloproteinases
(MMP) ADAMs
Granulocytes
Monocytes and Macrophages
Epithelial cells
Fibroblasts
Tissue inhibitor of metallo-
proteinases
(TIMPs-1-4)
α-macroglobulin
Cysteine
proteinases
Acidic Cathepsins B, S, H, L
Caspases
Inﬂ  ammatory cells
T cells
Epithelial cells
Inﬂ  ammatory cells
Endothelial cells
Epithelial cells
Cystatins A, C, S
α2-macroglobulin
Kininogens
Inhibitors of apoptosis pro-
teins (IAPs)
CmrA, p35, α1-PI
Abbreviations: COPD, chronic obstructive pulmonary disease; PMN, polymorphonuclear neutrophils; ADAMs, proteinases containing a disintegrin and a metalloproteinase 
domain; P-monocytes, pro-inﬂ  ammatory monocytes.International Journal of COPD 2008:3(2) 257
Proteinases in COPD
ligands and receptors for these molecules from cell surfaces 
to regulate inﬂ  ammation, apoptosis, and possibly ﬁ  brotic 
processes (Black et al 1997; Primakoff and Myles 2000; 
Black 2002). The disintegrin domain binds to integrins 
to regulate integrin-mediated cell adhesion and migration 
(Primakoff and Myles 2000).
MMPs are inhibited by α2-M and the four members of the 
tissue inhibitors of metalloproteinases family (TIMPs1-4), 
which are synthesized by connective tissue cells and leuko-
cytes and form non-covalent complexes with MMPs (Woess-
ner Jr 1991; Murphy and Docherty 1992). The inhibitors 
of ADAMs have not been fully elucidated, but ADAM-17 
is inhibited by TIMP-3 but not TIMP-1 or -2 (Amour et al 
1998; Black 2004).
Cysteine proteinases
Cathepsins B, H, L, and S have been implicated in COPD 
(Table 1). Cathepsin S and L are potent elastases in vitro 
(Mason et al 1986; Shi et al 1992) and contribute to 
macrophage-mediated ECM degradation. The main inhibi-
tors of cysteine proteinases are the cystatin superfamily, the 
kininogens, and α2-M (Henskens et al 1996).
Roles of proteinases in COPD
Evidence for roles of proteinases in COPD comes from stud-
ies of puriﬁ  ed proteinases, studies of clinical samples from 
COPD patients, and animal models of COPD.
In vitro studies of proteinases
Lung inﬂ  ammation and airspace enlargement
NE, CG, PR3, and GRZ have the potential to promote lung 
inﬂ  ammation in COPD patients, because they stimulate the 
release of pro-inﬂ  ammatory mediators from airway epithelial 
cells and macrophages in vitro (Hubbard et al 1991; Bedard 
et al 1993). Proteinases can also proteolytically cleave media-
tors to alter their biologic activities (Figure 1). MMPs-8 and -9 
cleave and activate various chemokines in vitro (Van Den 
Steen et al 2000; Balbin et al 2003). ADAM-17 and several 
MMPs shed and activate membrane-associated pro-TNF-α 
from macrophage surfaces (Primakoff and Myles 2000; Black 
2002; Churg et al 2003a). NE, MMP-12, and MMP-9 cleave 
elastin, and MMPs cleave α1-PI, generating fragments of these 
two molecules that are chemotactic for inﬂ  ammatory cells 
(Senior et al 1980; Hunninghake et al 1981). Serine, metallo-, 
and cysteine proteinases acting together can degrade elastin, 
interstitial collagens, and basement membrane proteins in 
vitro (Owen and Campbell 1999). All of these ECM proteins 
must be degraded when lung airspaces enlarge (Figure 1).
Airway pathologies
NE, MMP-9, and ADAMs-10 and -17 increase epithelial 
cell expression of MUC5AC, a major mucin protein, by 
activating epithelial growth factor receptor (EGFR) through 
shedding of membrane − bound pro-transforming growth 
factor (TGF)-α. This releases soluble, active TGF-α, which 
activates the EGFR (Kohri et al 2002; Shao et al 2004; 
Deshmukh et al 2005). NE, CG, and PR3 potently stimulate 
goblet cell degranulation (Sommerhoff et al 1990). Tissue 
kallikrein is a serine proteinase expressed by inﬂ  ammatory 
cells and submucosal glands. It also stimulates mucin synthe-
sis in airway epithelium in vitro by shedding and activating 
pro-EGF, another EGFR ligand (Casalino-Matsuda et al 
2006). NE also damages epithelial cells (Amitani et al 1991) 
and inhibits ciliary beat frequency of lung epithelial cells 
(Smallman et al 1984). Increased production and impaired 
clearance of mucus predispose COPD patients to recurrent 
bacterial airway infections, which amplify airway inﬂ  amma-
tion and injury (Figure 1).
Plasmin, MMP-9, NE, and ADAMs may also induce sub-
epithelial ﬁ  brosis in COPD airways, because they activate 
latent growth factors such as TGF-β (Taipale et al 1992; 
Yu and Stamenkovic 2000; Chua et al 2007) and insulin-
like growth factors in vitro (Fowlkes et al 1999; Mohan 
et al 2002) and these growth factors induce ﬁ  broblasts to 
synthesize and secrete interstitial collagens. However, it 
has not been determined whether these proteinases induce 
sub-epithelial ﬁ  brosis in the small airways of human COPD 
patients.
Studies of clinical samples from human 
COPD patients
In addition to the early observation that α1-PI-deﬁ  cient 
patients have early-onset emphysema, elegant studies from 
Damiano and colleagues (1986) further supported a role for 
NE in pulmonary emphysema. They localized NE bound 
to lung elastic ﬁ  bers and showed that the amount of NE 
bound to lung elastin is strongly correlated with the degree 
of emphysematous change. Since then, additional studies 
have conﬁ  rmed increased levels of NE in lung samples from 
COPD patients and demonstrated elevated levels of CG, PR3, 
uPA, and MMPs -1, -2, -8, -9, and -14 in various lung samples 
from smokers and COPD patients when compared with 
healthy subjects (Damiano et al 1986; Reilly and Chapman 
Jr 1988; Abboud et al 1998; Betsuyaku et al 1996; Finlay 
et al 1997; Betsuyaku et al 1999; Hill et al 1999; Betsuyaku 
et al 2000b; Cataldo et al 2000; Imai et al 2001; Beeh et al 
2003; Kang et al 2003).International Journal of COPD 2008:3(2) 258
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Although most studies have implicated proteinases from 
inﬂ  ammatory cells in COPD pathogenesis, proteinases pro-
duced by lung structural cells and immune cells also play impor-
tant roles (Figure 1). For example, cigarette smoke increases 
MMP production by lung epithelial cells (Imai et al 2001), and 
ﬁ  broblasts (Ning et al 2007). T lymphocytes from blood and 
BAL samples from COPD patients have increased levels of 
GRZ and perforin compared to samples from asymptomatic 
smokers and nonsmokers (Hodge et al 2006). Elevated levels 
of GRZ B in BAL samples from COPD patients are correlated 
with bronchial epithelial cell apoptosis, suggesting that GRZ B 
promotes epithelial cell death in the lung and contributes to 
airspace enlargement in COPD patients (Figure 1).
Animal models of COPD
Animal models of COPD provide the strongest evidence for 
the roles of proteinases in COPD.
Acute cigarette smoke exposure models
Acute exposure of mice to cigarette smoke for up for 30 days 
results in increases in lung PMN and macrophages and break-
down of lung collagen and elastin (Churg et al 2002). Studies 
of mice genetically deﬁ  cient in proteinases in these acute 
exposure models have identiﬁ  ed critical roles for MMP-12 
in regulating PMN inﬂ  ux and for thrombin and plasmin in 
regulating MMP-12 production (Figure 2). Cigarette smoke 
acutely upregulates macrophage MMP-12 levels by injuring 
lung capillaries (Burns et al 1989; Li et al 1996), leading to 
leakage of thrombin and plasmin into the alveolar space. 
Thrombin and plasmin cleave, thereby activating protease-
activated receptor -1 (PAR-1) on macrophages. Signaling 
through PAR-1 increases macrophage MMP-12 synthesis 
(Raza et al 2000; Churg et al 2007b). Macrophage-derived 
MMP-12 regulates PMN inﬂ  ux into the lung by shedding 
pro-TNF-α from activated macrophages, which likely up-
regulates E-selectin expression on endothelial cells to promote 
PMN transendothelial migration (Churg et al 2003a) and 
lung ECM degradation by PMN-derived serine proteinases 
(Figure 2). It is noteworthy that delivering human α1-PI to 
mice acutely exposed to cigarette smoke prevents PMN inﬂ  ux 
and ECM destruction. This is probably due to α1-PI inhibit-
ing both PMN serine proteinase-mediated ECM destruction 
and thrombin- or plasmin-induced increases in macrophage 
MMP-12 production (Churg et al 2003b, 2007b).
Chronic smoke exposure models
Exposure of WT mice to cigarette smoke for 3–6 months 
results in airspace enlargement, inflammation, and 
subepithelial ﬁ  brosis in the small airways, similar to that 
reported in human cigarette smokers (Hautamaki et al 1997; 
Martin et al 2001). Studies of proteinase-deﬁ  cient mice in 
this model have conﬁ  rmed roles for MMP-12 and NE in 
regulating chronic lung inﬂ  ammation and airspace enlarge-
ment (Figure 3) and for MMP-9 and/or MMP-12 in inducing 
subepithelial ﬁ  brosis in the small airways of smoke-exposed 
mice.
Mice deﬁ  cient in MMP-12 (MMP-12−/− mice) exposed 
to cigarette smoke for 6 months are completely protected 
from developing increased lung macrophage counts and 
from developing airspace enlargement (Hautamaki et al 
1997). MMP-12 degrades elastin and other ECM components 
to cause airspace enlargement (Figure 3). The decreased 
macrophage accumulation in MMP-12−/− mice is due to 
the lack of MMP-12-mediated cleavage of elastin, which 
generates elastin fragments that are chemotactic for blood 
monocytes (Figure 3) (Houghton et al 2006b). T lymphocyte 
products also play a critical role in driving MMP-12-medi-
ated inﬂ  ammation and airspace enlargement, since CD8+ 
T-cell-deﬁ  cient (CD8-/-) mice have a blunted inﬂ  ammatory 
response to cigarette smoke and fail to develop emphysema 
(Maeno et al 2007). This is mediated by a CD8+ T cell 
product, IFN-γ inducible protein 10 (IP-10), which induces 
production of MMP-12 and degradation of the lung ECM 
(Figures 1 and 3). This process may also contribute to COPD 
pathogenesis in human subjects, since lung tissue from 
human COPD patients contains increased numbers of Th1 
cells associated with increased levels of IP-10 and MMP-12 
(Grumelli et al 2004).
NE−/− mice are 60% protected from airspace enlargement 
and have decreased inﬂ  ux of PMN and monocytes into the 
lung compared to smoke-exposed WT mice (Shapiro et al 
2003) (Figure 3). NE likely contributes to airspace enlarge-
ment directly by degrading elastin and other ECM protein 
components of the alveolar walls (Shapiro et al 2003) 
(Figure 3), but the mechanisms by which NE promotes lung 
inﬂ  ammation are not clear.
When rodent airways are exposed acutely to cigarette 
smoke, increases in growth factor and collagen production 
are detectable within 2 h, and before inﬂ  ammation occurs 
in the airway walls (Churg et al 2006). This indicates that 
smoke directly promotes small airway subepithelial ﬁ  bro-
sis and that smoke-induced inﬂ  ammation and proteinase 
production are unnecessary for this process. However, in 
guinea pigs chronically exposed to cigarette smoke for up 
to 6 months, inﬂ  ammatory cell MMPs amplify this process, 
since delivering a synthetic dual inhibitor of MMPs-9 and -12 International Journal of COPD 2008:3(2) 259
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to these animals signiﬁ  cantly reduces small airway ﬁ  brosis 
(Churg et al 2007a). Studies of MMP inhibitors in human 
COPD patients are thus warranted to determine whether these 
proteinases play important roles in this important pathology 
in humans as well as mice.
Transgenic murine models
Transgenic mice over-expressing MMP-1 in the lung 
develop enlarged airspaces (D’Armiento et al 1992), which 
may either reﬂ  ect abnormal alveolar development or destruc-
tion of mature interstitial collagens by MMP-1. Assessment 
of transgenic mice inducibly over-expressing cytokines in 
the adult lung have conﬁ  rmed a role for immune-mediated 
inﬂ  ammation in airspace enlargement. Adult transgenic mice 
over-expressing a Th1 cytokine (IFN-γ), a Th2 cytokine 
(IL-13), or a cytokine with Th1 and Th2 activities (IL-18) in 
airway epithelial cells spontaneously develop striking lung 
inﬂ  ammation, increased lung levels of MMPs and cysteine 
proteinases, and airspace enlargement (Wang et al 2000; 
Zheng et al 2000; Kang et al 2007). In mice over-expressing 
IL-13, MMPs -9 and -12 play critical roles in promoting 
airspace enlargement, and MMP-12 also promotes inﬂ  am-
mation and drives the increased expression of other MMPs 
in the lung (Lanone et al 2002). In transgenic mice over-
expressing IFN-γ, cathepsin S stimulates lung epithelial 
apoptosis, lung inﬂ  ammation, and airspace enlargement 
(Zheng et al 2005).
Alveolar septal cell apoptosis models 
of airspace enlargement
Apoptosis of alveolar septal cells (Aoshiba et al 2001) and 
leukocytes (Aoshiba et al 2001; Hodge et al 2005) occurs in 
the lungs of COPD patients, and apoptosis of the endothelial 
and epithelial cells that make up the alveolar walls contributes 
to the development of emphysema. Septal cell apoptosis and 
airspace enlargement in the absence of overt lung inﬂ  ammation 
can be induced rapidly in experimental animals by: 1) pharma-
cologic blockade of vascular endothelial growth factor recep-
tors in rodents (Kasahara et al 2000); and 2) transfection of 
murine alveolar epithelial cells with caspase-3, a pro-apoptotic 
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Figure 2 Interactions between proteinases regulate inﬂ  ammation and matrix destruction in mice acutely exposed to cigarette smoke. Cigarette smoke drives macrophage 
MMP-12 production, at least in part by inducing thrombin- and plasmin-mediated activation of protease-activated receptor-1 (PAR-1) on macrophages. MMP-12 stimulates 
PMN accumulation in the lung by shedding pro-TNF-α from the macrophage surface, generating soluble, active TNF-α. Active TNF-α stimulates PMN trans-endothelial 
migration by up-regulating endothelial E selectin expression. PMN proteinases, such as neutrophil elastase (NE), amplify macrophage MMP-12 mediated destruction of the 
lung ECM.International Journal of COPD 2008:3(2) 260
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cysteine proteinase (Aoshiba et al 2003). However, increased 
elastase activity due to acidic proteinase(s) is detected in BAL 
samples after transfection of alveolar epithelial cells with 
caspase-3 (Aoshiba et al 2003). Thus, proteinases released 
from dying structural cells may degrade the lung ECM, thereby 
acting synergistically with septal cell apoptosis to cause loss 
of alveolar units and airspace enlargement (Figure 1).
Interactions between proteinases 
and other mediators and pathways 
in COPD
Interactions between different classes of proteinases and 
between proteinases and other molecules present in COPD 
lungs either amplify or inhibit proteinase production, lung 
inﬂ  ammation, and airspace enlargement in COPD lungs.
Studies of the NE−/− and MMP-12−/− mice exposed chroni-
cally to cigarette smoke demonstrated interactions between 
these two classes of proteinases (Figure 3), with MMP-12 
cleaving and inactivating α1-PI to increase NE-mediated 
lung injury, and NE cleaving and inactivating TIMP-1 to 
amplify MMP-12-mediated lung destruction (Shapiro et al 
2003). Proteinases also interact with ROS present in cigarette 
smoke itself and are generated by phagocytes activated by 
cigarette smoke. ROS activate proMMPs in vitro and have 
been thought to exacerbate lung inﬂ  ammation and injury in 
COPD patients (Owen 2005). Consistent with this hypothesis, 
mice transgenically over-expressing the antioxidant enzyme 
Cu-Zn superoxide dismutase in the lung are protected from 
developing chronic lung inﬂ  ammation, increased lung MMP 
levels, and emphysema in response to intratracheal instil-
lation of porcine pancreatic elastase, or chronic exposure 
to cigarette smoke (Foronjy et al 2006). However, mice 
deﬁ  cient in a phagocyte-speciﬁ  c component of the NADPH 
oxidase, which generates superoxide anions (O2
−), develop 
greater airspace enlargement in response to cigarette smoke 
than WT mice (Kassim et al 2005). This is due to ROS-
mediated inactivation of MMPs via oxidative inactivation of 
residues in the catalytic domain of MMPs (Fu et al 2003a). 
Thus, phagocyte-derived O2
− (and ROS derived from O2
−) in 
COPD lungs may constrain rather than promote phagocyte 
MMP-mediated lung injury (Fu et al 2003b; Kassim et al 
2005). This may be one reason that clinical trials have failed 
to demonstrate protective effects of antioxidant supplementa-
tion in COPD patients (Rahman and MacNee 1996).
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Figure 3 Interactions between proteinases regulate inﬂ  ammation and ECM destruction in mice chronically exposed to cigarette smoke. Neutrophil elastase (NE) promotes 
inﬂ  ammation and ECM destruction in mice chronically exposed to cigarette smoke by increasing the inﬂ  ux of PMN and monocytes into the lung (by unknown mechanisms), 
and by cleaving and inactivating TIMPs to promote MMP-12 mediated ECM degradation. MMP-12 ampliﬁ  es NE-mediated lung inﬂ  ammation and destruction by cleaving and 
inactivating α1-PI, the major inhibitor of NE in the lower respiratory tract. Fragments of elastin generated by MMP-12 (and possibly by NE) amplify MMP-12-mediated lung 
injury by stimulating the recruitment of blood monocytes into the lung.International Journal of COPD 2008:3(2) 261
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Molecular mechanisms 
for proteinase-mediated lung 
injury in COPD
In order to contribute to pathologies in COPD, proteinases 
must overcome the effects of proteinase inhibitors, which 
are present at micromolar concentrations in extracellular 
ﬂ  uids. Proteinases circumvent the effects of extracellular 
inhibitors by inactivating, evading, or overwhelming them 
(Figure 4).
Inactivation of proteinase inhibitors
Serpins can be cleaved and inactivated by MMPs (Desrochers 
and Weiss 1988; Desrochers et al 1991, 1992; Sires et al 
1994; Gronski Jr et al 1997), NE (Cantin et al 1995), cathep-
sin B (Johnson and Travis 1977), and bacterial proteinases 
(Sponer et al 1991). Serine proteinases cleave and inactivate 
TIMPs (Okada et al 1988). Proteolytic inactivation of α1-PI 
and TIMP-1 by MMP-12 and NE occurs in the cigarette 
smoke exposure model of emphysema in mice (Shapiro 
et al 2003).
ROS present in cigarette smoke or released by leukocytes 
activated by smoke inactivate α2-M, and α1-PI, and SLPI in 
vitro by converting the methionine at the active sites of these 
inhibitors to methionine sulfoxide, which reduces their capac-
ity to inhibit serine proteinases (Carp and Janoff 1979, 1980a, 
1980b; Reddy et al 1994). Whether oxidative inactivation of 
proteinase inhibitors occurs in COPD patients is controver-
sial, since some studies have detected oxidized α1-PI in lung 
samples from COPD patients but others have not (Gadek et al 
1979; Stone et al 1983; Abboud et al 1985). Also, ROS can 
inactivate proteinases as outlined above. Global analysis of 
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3. Membrane-
binding
5. Sequestered 
microenvironment
Cell-matrix adhesion
4. Binding 
to ECM
2. Quantum 
proteolysis PMN
Matrix
Proteinases 
Stored in 
granules
Figure 4 Mechanisms by which proteinases circumvent proteinase inhibitors in the extracellular space to cause lung injury in COPD. PMN store preformed proteinases 
within intracellular granules, and proteinases are released into the extracellular space when pro-inﬂ  ammatory mediators induce PMN degranulation. Proteinases freely 
released by PMN are inhibited when they form complexes with extracellular inhibitors. However, proteinases can circumvent inhibitors by: 1) cleaving or degrading inhibi-
tors; 2) being released at very high concentrations into the extracellular space, thereby overwhelming inhibitors; 3) binding to cell membranes in inhibitor-resistant forms; 
4) binding to matrix substrates in inhibitor-resistant forms; or 5) being released into sequestered microenvironments formed by tight adhesion of PMN to ECM into which 
diffusion of large inhibitors is impaired.International Journal of COPD 2008:3(2) 262
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the oxidation state of proteinase inhibitors in lung samples 
from COPD patients may not accurately reﬂ  ect events in cel-
lular microenvironments. ROS are short-lived molecules and 
are active only at short distances from the cells generating 
them before they are inactivated by antioxidants. It is likely 
that ROS and proteinases released into microenvironments 
around activated leukocytes act synergistically to locally 
inactivate inhibitors (or proteinases) and promote (or reduce) 
extracellular proteolysis.
Evasion of inhibitors
Proteinases can evade inhibitors by being released into 
sequestered microenvironments, binding tightly to substrates, 
or binding to cell surfaces (Figure 4).
Sequestered microenvironments
Integrin-mediated adhesion of inﬂ  ammatory cells to matrix 
or to cells results in the formation of a "sealed" micro-
environment, which prevents large inhibitors such as α1-PI 
(Campbell and Campbell 1988) and α2-M (Wright and Sil-
verstein 1984) from penetrating into zones of contact between 
the cells and their substrates (Figure 4).
Tight binding of proteinases to substrates
NE binds very stably to elastin in an active form, and α1-PI 
and SLPI have reduced effectiveness against elastin-bound 
NE compared to soluble NE (Bruch and Bieth 1986; Morrison 
et al 1990, 1999). Since NE is bound to interstitial elastin 
in human emphysematous lungs (Damiano et al 1986), lung 
elastin-bound NE likely retains catalytic activity and contrib-
utes critically to destruction of elastin ﬁ  bers in pulmonary 
emphysema (Figure 4). MMPs-1, -2, and -9 bind to various 
ECM proteins, which may increase the retention, stability, 
and bioactivity of proteinases in the lung and facilitate their 
roles in extracellular proteolysis (Murphy et al 1992; Allan 
et al 1995).
Membrane binding of proteinases
MT-MMP and ADAMs are integral membrane proteinases, 
and some members of these families are resistant to inhibi-
tion by physiologic inhibitors. For example, ADAM-17 is 
resistant to inhibition by TIMPs-1 and -2 but not TIMP-3 
(Amour et al 1998), and MT1-MMP is resistant to inhibition 
by TIMP-1 but not TIMP-2 (D’Ortho et al 1998). NE, CG, 
PR3, MMPs-8 and -9 (which lack transmembrane domains 
or glycosylphosphatidyl-inositol anchors) are also expressed 
on the surface of activated PMN (Owen et al 1995a, 1995b, 
2003, 2004; Owen and Campbell 1998; Campbell et al 2000) 
(Figure 4). These surface-bound proteinases potently degrade 
lung ECM proteins and proteinase inhibitors and induce 
goblet cell degranulation (Takeyama et al 1998; Owen et al 
1995b, 2003, 2004). However, unlike the soluble enzymes, 
the membrane-bound forms of these proteinases are resistant 
to inhibition by physiologic inhibitors (Owen et al 1995b, 
2003, 2004; Owen and Campbell 1998; Campbell et al 
2000). The inhibitor-resistance of membrane-bound NE is 
due to positive residues in NE binding to negatively charged 
sulfate groups in PMN plasma membrane proteoglycans 
(Campbell and Owen 2007), but the mechanism underlying 
the resistance of other cell-surface proteinases to inhibition is 
not known. Whatever the mechanism involved, catalytically 
active but inhibitor-resistant membrane-bound proteinases 
are well equipped to play critical roles in pathologies in 
COPD patients.
Overwhelming of inhibitors
Proteinases may overwhelm inhibitors when massive quanti-
ties of enzymes are released from large numbers of inﬂ  am-
matory cells, or when high concentrations of proteinases are 
released from individual cells (quantum proteolysis).
Brisk inﬂ  ux of inﬂ  ammatory cells
During acute exacerbations of COPD, there is brisk inﬂ  ux 
of inﬂ  ammatory cells into the airways. Active forms of NE, 
MMP-8, and MMP-9 released from these cells are detectable 
in lung secretions from COPD patients (Burnett et al 1987; 
Yoshioka et al 1995; Betsuyaku et al 1999; Hill et al 1999). 
Macrophage clearance of PMN recruited into the lung can 
be impaired in COPD patients by several mechanisms. First, 
cigarette smoke impairs expression of recognition molecules 
for apoptotic PMN on the macrophage surface (Hodge et al 
2007). Second, NE cleaves recognition molecules for apop-
totic PMN from the macrophage surface (Vandivier et al 
2002). Third, when PMN ingest Hemophilus inﬂ  uenzae, 
which frequently colonizes the respiratory tract of COPD 
patients, PMN necrosis is rapidly induced (Naylor et al 2007). 
All of these processes hinder noninﬂ  ammatory macrophage 
removal of PMN, instead promoting PMN necrosis and 
release of proteinases into the lung.
Quantum proteolysis and PiZZ α1-PI deﬁ  ciency
NE is present at millimolar concentrations in each azurophil 
granule of PMN, which is more than 100-fold higher than the 
concentration of α1-PI in plasma (Liou and Campbell 1995). 
The release of an azurophil granule into the extracellular 
space is thus accompanied by a transient burst of proteolytic 
activity (Figure 4), which persists until the granule contents International Journal of COPD 2008:3(2) 263
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diffuse from this site, and the proteinase-inhibitor ratio 
falls below 1:1 (Liou and Campbell 1995). Individuals with 
severe, inherited deﬁ  ciency of α1-PI have severe reductions in 
plasma levels of α1-PI (less than 4 μM in PiZZ α1-PI deﬁ  cient 
individuals versus ~30 μM in healthy PiMM individuals) due 
to loop sheet polymerization of PiZ mutant protein within 
hepatocytes, leading to reduced hepatocyte secretion of PiZ 
α1-PI (Lomas et al 1992). Quantum bursts of NE-mediated 
proteolytic activity associated with PMN migrating on ECM 
proteins are 10-fold larger in area and 4-fold longer in dura-
tion when PMN are bathed in serum from PiZZ patients 
compared to serum from healthy PiMM subjects (Campbell 
et al 1999), due to defective conﬁ  nement of PMN-derived 
NE-mediated ECM degradation. Other mechanisms lead-
ing to excessive ECM destruction and lung inﬂ  ammation in 
patients with severe, inherited deﬁ  ciency of α1-PI include 
the formation of polymers of PiZ α1-PI mutant proteins in 
the lung, which not only are ineffective inhibitors of NE, 
but also have chemotactic activity for PMN (Mahadeva et al 
2005; Lomas 2006).
Potential for proteinase inhibition 
in COPD
Based upon the available evidence, strategies to directly 
inhibit proteinases or to decrease the lung proteinase burden 
by decreasing inﬂ  ammatory cell inﬂ  ux into the lung may 
be effective in limiting proteinase-induced lung injury in 
COPD patients.
Direct proteinase inhibition
Supplementation with physiologic proteinase 
inhibitors
This strategy is effective in murine models of COPD and in 
human subjects with COPD secondary to α1-PI deﬁ  ciency. 
Delivering α1-PI systemically or by the inhaled route to 
smoke-exposed mice inhibits smoke-induced lung inﬂ  amma-
tion and airspace enlargement (Churg et al 2003b; Pemberton 
et al 2006). Alpha1-PI augmentation therapy is being used in 
the USA in α1-PI-deﬁ  cient patients who have impaired lung 
function. Observational studies using this strategy conﬁ  rm 
that it reduces bronchial inﬂ  ammation, slows the rate of 
decline in lung function, increases quality-of-life scores, and 
decreases exacerbation frequency in α1-PI-deﬁ  cient patients 
(Stockley et al 2002a; Juvelekian and Stoller 2004).
Synthetic proteinase inhibitors
Synthetic inhibitors have several advantages over physi-
ologic inhibitors, including their resistance to oxidative and 
proteolytic inactivation and their effectiveness against both 
soluble and membrane-bound forms of proteinases (Owen 
et al 1995b, 2003, 2004). In animals exposed to cigarette 
smoke, or in transgenic mice over-expressing IL-13, deliv-
ering synthetic inhibitors of serine, metallo-, and cysteine 
proteinases by the systemic, oral, or inhaled routes blocks 
lung inﬂ  ammation and airspace enlargement (Churg et al 
2002; Lanone et al 2002; Stockley et al 2002b; Wright et al 
2002; Pemberton et al 2005). Daily oral delivery of synthetic 
MMP inhibitors not only prevents airspace enlargement 
in mice chronically exposed to cigarette smoke, but also 
prevents progression of lung inﬂ  ammation and airspace 
enlargement if therapy is initiated after emphysema has been 
established (Martin et al 2001). Synthetic inhibitors may also 
have potential in limiting the airﬂ  ow obstruction produced 
by small airway ﬁ  brosis, since a synthetic compound that 
inhibits both MMP-9 and MMP-12 effectively blocks small 
airway ﬁ  brosis in cigarette smoke-exposed guinea pigs 
(Churg et al 2007a).
Anti-inﬂ  ammatory strategies
Approaches to reducing inﬂ  ammatory cell recruitment into 
the lung and activation of inﬂ  ammatory cells would not only 
reduce the lung burden of inﬂ  ammatory cell-derived protein-
ases but also that of other pathogenetic molecules generated 
by inﬂ  ammatory cells in COPD patients such as ROS and 
pro-inﬂ  ammatory mediators. Inhibitors of phosphodiester-
ase E4 (PDE4), the major PDE isoenzyme in inﬂ  ammatory 
cells, decrease inflammatory cell migration, activation, 
and release of proteinases in vitro. Roﬂ  umilast (a PDE4 
inhibitor) also protects mice from cigarette-smoke induced 
lung inﬂ  ammation and airspace enlargement (Martorana 
et al 2005). Short-term clinical trials of phosphodiesterase 
E4 inhibitors in COPD patients have indicated that these 
inhibitors decrease lung inﬂ  ammation, lung proteinases, and 
pro-inﬂ  ammatory mediators, increase post bronchodilator 
forced expiratory volume in one second (Martina et al 2006; 
Calverley et al 2007; Grootendorst et al 2007), and reduce 
the frequency of acute exacerbations (Martina et al 2006; 
Calverley et al 2007). Statins (hydroxymethylglutaryl CoA 
reductase inhibitors) have diverse anti-inﬂ  ammatory effects 
and also represent a potential new approach to COPD. This 
is supported by a recent study showing that simvastatin 
reduces lung inflammation, airspace enlargement, and 
pulmonary hypertension in cigarette smoke-exposed rats 
(Lee et al 2005). Several recent retrospective analyses have 
reported reduced morbidity and mortality in COPD patients International Journal of COPD 2008:3(2) 264
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taking statins for cardiovascular disease (Gueders et al 2005; 
Mancini et al 2006).
Other potential approaches to reduce inﬂ  ammatory cell 
inﬂ  ux into the lung include anti-oxidant supplementation, 
inhibiting the transcription factor NF-κB, which drives the 
production of several pro-inﬂ  ammatory molecules caus-
ing inﬂ  ammation in COPD lungs (Retamales et al 2001; 
Szulakowski et al 2006) and inhibitors of chemokine receptors 
(Donnelly and Barnes 2006). Histone deacetylases, which are 
enzymes that switch off transcription of pro-inﬂ  ammatory 
genes, are inactivated in COPD patients (Ito et al 2005) and 
represent another potential drug target in COPD patients.
Conclusions and future directions
There is now substantial evidence from animal model systems 
that proteinases make important contributions to pathologies 
in COPD and that proteinase inhibition and anti-inﬂ  ammatory 
strategies effectively limit smoke-induced lung injury in 
mice. However, there are critical gaps in our knowledge about 
the roles of proteinases not only in pathogenesis of human 
COPD, but also in repair processes in the lung in COPD, and 
in lung biology in general.
It is important to note that murine model systems of COPD 
have limitations. Mice lack submucosal glands and do not 
develop mucus hypersecretion or acute exacerbations in the 
murine cigarette smoke exposure model. Mice also have fewer 
circulating PMN than humans and do not express MMP-1. 
The role of MMP-12 in human disease must be clariﬁ  ed. Early 
studies failed to detect increased expression of MMP-12 in 
lung samples (Finlay et al 1997; Imai et al 2001), but more 
recent studies using other techniques have demonstrated 
increased levels of MMP-12 in human COPD (Grumelli et al 
2004; Molet et al 2005; Woodruff et al 2005; Demedts et al 
2006). Thus, PMN-derived serine proteinases and MMPs in 
addition to MMP-12 may be important in human COPD. The 
challenge for the future will be to determine which proteinases 
play critical roles not only in airspace enlargement but also 
in airway pathologies in human COPD patients.
The biologic roles of proteinases expressed in the lung 
have also not been fully elucidated. Evidence is accumulat-
ing that some proteinases have both beneﬁ  cial as well as 
deleterious roles in the murine lung. NE plays critical roles 
in bacterial killing in mice (Belaaouaj et al 1998), MMP-8 
reduces lung inﬂ  ammation (Owen et al 2004; Gueders et al 
2005), and MMP12 has anti-tumor activities (Houghton et al 
2006a). If these proteinases have similar beneﬁ  cial activities 
in the human lung, this may limit the usefulness of inhibitors 
of these proteinases in COPD patients, who are at increased 
risk for developing respiratory tract infections and lung can-
cer (Skillrud et al 1986). Little is also known about repair 
processes in the COPD lung in general, or whether protein-
ases participate in lung repair in COPD. Studies of MMP-9 
deﬁ  cient mice in bleomycin-mediated lung injury suggest 
that MMP-9 might play roles in epithelial repair processes 
in the injured lung (Betsuyaku et al 2000a), and it is likely 
that other proteinases contribute to repair of the injured lung 
in COPD patients.
There have been no long-term clinical trials of synthetic 
proteinase inhibitors or anti-inﬂ  ammatory agents in COPD 
patients due mainly to the high cost of such trials. In addition, 
we currently lack knowledge about appropriate biomarkers 
for studying the effectiveness of new treatment strategies 
in COPD patients. Nevertheless, based upon the evidence 
available, randomized clinical trails to test the safety and 
efﬁ  cacy of proteinase inhibitors and anti-inﬂ  ammatory agents 
are justiﬁ  ed in COPD patients.
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